BioMarin Pharmaceutical (BMRN) Projected to Post Quarterly Earnings on Wednesday

BioMarin Pharmaceutical (NASDAQ:BMRN) will likely be issuing its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect the company to announce earnings of $0.80 per share and revenue of $834.3160 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

BioMarin Pharmaceutical Trading Down 0.1%

Shares of BioMarin Pharmaceutical stock opened at $59.87 on Tuesday. The company has a current ratio of 4.83, a quick ratio of 3.10 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical has a twelve month low of $50.76 and a twelve month high of $73.51. The firm has a market capitalization of $11.50 billion, a PE ratio of 22.51, a P/E/G ratio of 0.65 and a beta of 0.26. The firm’s 50-day moving average price is $57.38 and its 200 day moving average price is $55.96.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of institutional investors and hedge funds have recently made changes to their positions in BMRN. CIBC Private Wealth Group LLC boosted its stake in shares of BioMarin Pharmaceutical by 38.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 179 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of BioMarin Pharmaceutical during the 3rd quarter worth approximately $40,000. Parallel Advisors LLC increased its position in BioMarin Pharmaceutical by 62.2% during the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after buying an additional 295 shares in the last quarter. Meeder Asset Management Inc. increased its position in BioMarin Pharmaceutical by 1,974.1% during the 4th quarter. Meeder Asset Management Inc. now owns 1,763 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,678 shares in the last quarter. Finally, FORA Capital LLC purchased a new stake in shares of BioMarin Pharmaceutical during the fourth quarter worth about $224,000. 98.71% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BMRN. Wall Street Zen downgraded shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Stifel Nicolaus reiterated a “hold” rating and issued a $61.00 price objective (down from $73.00) on shares of BioMarin Pharmaceutical in a research report on Thursday, November 6th. Tudor Pickering set a $88.00 target price on BioMarin Pharmaceutical in a research note on Monday, November 3rd. HC Wainwright lifted their target price on BioMarin Pharmaceutical from $55.00 to $60.00 and gave the company a “neutral” rating in a research report on Monday, December 22nd. Finally, Canaccord Genuity Group raised BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and upped their price target for the company from $84.00 to $98.00 in a research note on Tuesday, January 20th. Seventeen investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $88.29.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.